These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38572952)

  • 1. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
    Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
    Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.
    Nagakubo Y; Hirotsu Y; Yoshino M; Amemiya K; Saito R; Kakizaki Y; Tsutsui T; Miyashita Y; Goto T; Omata M
    Sci Rep; 2024 May; 14(1):12480. PubMed ID: 38816489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer.
    Kodama H; Murakami H; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ko R; Ono A; Kenmotsu H; Naito T; Matsumoto S; Goto K; Shimizu T; Gon Y; Takahashi T
    Thorac Cancer; 2024 Jul; 15(21):1665-1672. PubMed ID: 38898747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
    Hirotsu Y; Nakagomi T; Nagakubo Y; Goto T; Omata M
    Sci Rep; 2024 Jan; 14(1):1594. PubMed ID: 38238401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
    Saito A; Terai H; Kim TJ; Emoto K; Kawano R; Nakamura K; Hayashi H; Takaoka H; Ogata A; Kinoshita K; Ito F; Shigematsu L; Okada M; Fukushima T; Mitsuishi A; Shinozaki T; Ohgino K; Ikemura S; Yasuda H; Kawada I; Soejima K; Nishihara H; Fukunaga K
    Cancer Med; 2024 Feb; 13(4):e7077. PubMed ID: 38457233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
    Murakami S; Yokose T; Shinada K; Isaka T; Katakura K; Ushio R; Kondo T; Kato T; Ito H; Saito H
    Thorac Cancer; 2022 Nov; 13(22):3217-3224. PubMed ID: 36203199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Current Achievements of Multi-Gene Panel Tests in Clinical Settings for Patients with Non-Small-Cell Lung Cancer.
    Sakaguchi T; Iketani A; Esumi S; Esumi M; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Yasui H; Taguchi O; Hataji O
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.
    Sakaguchi T; Iketani A; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Taguchi O; Hataji O
    Thorac Cancer; 2021 Feb; 12(4):462-467. PubMed ID: 33314600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological criteria for multiplex gene-panel testing using next-generation sequencing in non-small cell lung cancer.
    Mizote S; Matsumura M; Sekiya M; Sugiyama M; Sekine A; Kobayashi N; Kataoka T; Iwashita H; Okudela K
    Cancer Treat Res Commun; 2022; 32():100614. PubMed ID: 35878517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.
    Takahashi T; Nishio M; Nishino K; Yoshiki Y; Shiraiwa N; Emir B; Iadeluca L; Yatabe Y; Nishio K
    Cancer Sci; 2023 Jun; 114(6):2524-2533. PubMed ID: 36751989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible False Results With cobas
    Kanaoka K; Tamiya A; Inagaki Y; Taniguchi Y; Nakao K; Takeda M; Matsuda Y; Okishio K; Shimizu S
    Anticancer Res; 2023 Jun; 43(6):2771-2776. PubMed ID: 37247929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
    Sakaguchi T; Iketani A; Esumi S; Esumi M; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Yasui H; Taguchi O; Hataji O
    Sci Rep; 2023 Aug; 13(1):13759. PubMed ID: 37612335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples.
    Nemoto D; Yokose T; Katayama K; Murakami S; Kato T; Saito H; Suzuki M; Eriguchi D; Samejima J; Nagashima T; Ito H; Yamada K; Nakayama H; Masuda M
    Thorac Cancer; 2021 Jan; 12(2):194-200. PubMed ID: 33185331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.
    Kumbrink J; Demes MC; Jeroch J; Bräuninger A; Hartung K; Gerstenmaier U; Marienfeld R; Hillmer A; Bohn N; Lehning C; Ferch F; Wild P; Gattenlöhner S; Möller P; Klauschen F; Jung A
    Pathol Oncol Res; 2024; 30():1611590. PubMed ID: 38605929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer.
    Iwama E; Yamamoto H; Okubo F; Ijichi K; Ibusuki R; Shiaraishi Y; Yoneshima Y; Tanaka K; Oda Y; Okamoto I
    Thorac Cancer; 2023 Aug; 14(23):2288-2296. PubMed ID: 37345344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
    He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor molecular profiling of NSCLC patients using next generation sequencing.
    Tsoulos N; Papadopoulou E; Metaxa-Mariatou V; Tsaousis G; Efstathiadou C; Tounta G; Scapeti A; Bourkoula E; Zarogoulidis P; Pentheroudakis G; Kakolyris S; Boukovinas I; Papakotoulas P; Athanasiadis E; Floros T; Koumarianou A; Barbounis V; Dinischiotu A; Nasioulas G
    Oncol Rep; 2017 Dec; 38(6):3419-3429. PubMed ID: 29130105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
    Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.